Starpharma Holdings Ltd
ASX:SPL
Starpharma Holdings Ltd
Research & Development
Starpharma Holdings Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Starpharma Holdings Ltd
ASX:SPL
|
Research & Development
-AU$12.1m
|
CAGR 3-Years
14%
|
CAGR 5-Years
10%
|
CAGR 10-Years
3%
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Research & Development
-AU$17.9m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Research & Development
-AU$30m
|
CAGR 3-Years
-58%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-9%
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Research & Development
-AU$144k
|
CAGR 3-Years
76%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Research & Development
-AU$66.9m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Research & Development
-AU$4.4m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
Starpharma Holdings Ltd
Glance View
Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. The company is headquartered in Melbourne, Victoria and currently employs 50 full-time employees. The company went IPO on 2000-09-28. The firm is engaged in development of dendrimer products for pharmaceutical, life science and other applications. The firm has two core development programs: VivaGel portfolio and Dendrimer Enhanced Product (DEP) drug delivery. VivaGel BV for bacterial vaginosis (BV) is a women’s health product. The company is available for sale under the brand names, Betafem BV Gel (UK), Betadine BV (Europe), Betadine BV Gel (Asia) and Fleurstat BVgel (Australia and New Zealand). DEP is a drug delivery platform, which provides demonstrated reproducible preclinical benefits across various internal and partnered DEP programs, including improved efficacy, safety, and survival. The firm has three internal DEP products includes DEP docetaxel, DEP cabazitaxel and DEP irinotecan. These internal DEP Products are in clinical development. The firm develops several products internally and others via commercial partnerships.
See Also
What is Starpharma Holdings Ltd's Research & Development?
Research & Development
-12.1m
AUD
Based on the financial report for Jun 30, 2025, Starpharma Holdings Ltd's Research & Development amounts to -12.1m AUD.
What is Starpharma Holdings Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
3%
Over the last year, the Research & Development growth was 22%. The average annual Research & Development growth rates for Starpharma Holdings Ltd have been 14% over the past three years , 10% over the past five years , and 3% over the past ten years .
